What's Happening?
Researchers have identified critical factors affecting the manufacturability of bispecific antibodies (BsAbs), a class of therapeutic compounds that target two different antigens simultaneously. Since their first approval in 2014, 19 BsAbs have been approved
globally, with approximately 250 in development. The study, led by Laura A. Palomares at Universidad Nacional Autónoma de Mexico, highlights the challenges in producing BsAbs at scale, including low yields and stability issues. The research emphasizes the importance of BsAb architecture in determining growth, productivity, and binding efficiency. Symmetric heavy-chain scFv fusion BsAbs showed up to 70% higher productivity compared to other designs, suggesting that avoiding light-chain modifications and maintaining symmetric assembly can enhance manufacturability.
Why It's Important?
The findings are significant for the biopharmaceutical industry, which is keen to improve the efficiency of BsAb production. As these antibodies move from laboratory research to clinical and commercial applications, understanding the structural factors that influence manufacturability can lead to more cost-effective and scalable production processes. This could accelerate the availability of BsAbs for treating various diseases, including cancer and autoimmune disorders, potentially benefiting patients by providing more effective treatment options. The research also underscores the need for continued innovation in bioprocess engineering to overcome existing manufacturing challenges.
What's Next?
Future research will focus on determining the in vivo functionality of the BsAb formats developed in this study, particularly their ability to neutralize viruses like Zika after crossing the blood-brain barrier. These experiments will provide valuable insights for scientists involved in BsAb design and could lead to the development of new therapeutic strategies. The ongoing exploration of BsAb architectures will likely continue to refine production techniques and improve the therapeutic efficacy of these complex molecules.
